How a protein called prohibitin-1 helps protect the heart during sepsis
Official title: Determinants of cardioprotection by circulating prohibitin-1 during sepsis
Funded at University of Iowa · NIH-11060899 · Data updated 2026-11-12
This study is looking at a protein called prohibitin-1 in the blood to see how it helps protect the heart during sepsis, a serious condition that causes inflammation, and it aims to find new ways to treat and diagnose heart issues related to sepsis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | April 11, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $398,863 |
| NIH project number | 5R01HL167087-03 |
| Project ID | NIH-11060899 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are experiencing sepsis or are at risk of developing septic complications.
✕Less likely to help
Patients who do not have sepsis or related acute inflammatory conditions may not benefit from this research.
What this research studies
This research investigates the role of prohibitin-1, a protein found in the blood, in protecting the heart during sepsis, a severe inflammatory condition. The study aims to understand how prohibitin-1 influences heart function and metabolism when the body is under stress from sepsis. By examining the mechanisms through which this protein operates, researchers hope to identify new targets for treatment and biomarkers for diagnosis. The approach includes using mouse models to observe the effects of prohibitin-1 on heart health during sepsis.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve heart function and reduce mortality in patients suffering from sepsis.
How similar studies have gone: Previous research has shown promising results in understanding the role of prohibitin-1 in cellular functions, suggesting potential for success in this novel approach.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Anderson, Ethan John — University of Iowa
- Study coordinator: Anderson, Ethan John
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.